Shield C F
University of Kansas School of Medicine, Wichita.
Clin Transpl. 1990:265-74.
The OKT3 induction protocol, when compared to a conventional drug protocol, resulted in an improvement in both short- and long-term patient and graft survival, especially in patients receiving a primary transplant. The 1-year allograft survival in primary transplants receiving OKT3 induction was 91% and the T1/2 of 13.5 years. This was accomplished while still being able to minimize the total drug dose of Aza, Pred, and CsA, thereby minimizing clinical complications. The use of OKT3 did not increase infections or malignant complications. This resultant significant improvement supports the passenger leukocyte theory of stimulation for allograft rejection. Further graft survival improvement in histodisparate allografts might be accomplished by OKT3 induction in concert with other methodologies that can control this cell type. The HLA antigens may not be as large an obstacle to grafting as previously suggested.
与传统药物方案相比，OKT3诱导方案可提高患者和移植物的短期及长期存活率，尤其是在接受初次移植的患者中。接受OKT3诱导的初次移植中，1年移植物存活率为91%，半衰期为13.5年。在实现这一结果的同时，仍能够将硫唑嘌呤、泼尼松和环孢素的总药物剂量降至最低，从而将临床并发症减至最少。使用OKT3不会增加感染或恶性并发症。这一显著改善结果支持了移植物排斥刺激的过客白细胞理论。通过OKT3诱导并结合其他能够控制此类细胞的方法，可能会进一步提高组织不相配同种异体移植物的存活率。HLA抗原可能并不像之前认为的那样是移植的巨大障碍。
